The Electronic Clinical Dementia Rating (eCDR): A Promising Tool for Dementia Screening

By Staff Writer

September 25, 2023

The Electronic Clinical Dementia Rating (eCDR) is a digital tool showing potential in dementia screening and staging, according to a recent cross-sectional study. The eCDR, which can be self-administered remotely and scored automatically, was compared to the Clinical Dementia Rating (CDR), a widely used instrument for detecting and staging dementia due to Alzheimer disease.

Recent study from the USA


The study involved 288 participants, aged 55 years and above, from three Alzheimer Disease Research Centers and the Brain Health Registry. Participants completed both the CDR and eCDR, with the latter being completed remotely and unsupervised.

The findings revealed that the eCDR showed high concordance with the CDR at item, box, and global levels. The concordance ranged from 80% for memory to 99% for personal care. The global score concordance rate was 81%. The study also found that eCDR scores correlated with CDR-SB scores with moderate to high accuracy.

These results suggest that the eCDR is a valid tool for screening and assessing cognitive and functional decline related to Alzheimer disease in older adults. The study emphasises the need for further validation and optimization of eCDR content and scoring in diverse populations and remote settings.

How does this work?

The eCDR works by allowing participants to complete the dementia screening and staging process remotely, using their own device. It is designed to be user-friendly and can be self-administered without supervision. Once the participant completes the eCDR, the tool automatically scores the results. This digital tool is structured similarly to the CDR, rating cognitive and functional impairment across multiple domains. However, unlike the CDR, the eCDR does not rely on clinical judgement to assign scores, instead using an automated scoring algorithm. This feature, along with its remote administration capability, makes the eCDR a potentially more efficient and accessible tool for dementia screening and staging. 


This could lessen the burden of in-clinic research visits by using remote administration with automated scoring could revolutionise dementia screening and assessment, facilitating clinical research, clinical trials, and healthcare.



Reference url

Recent Posts

oral cancer East Africa
   

Oral Cancer in East Africa: The Need for Early Detection

💡 Did you know that Toombak use is a leading risk factor for oral cancer in East Africa?

A recent scoping review sheds light on the shocking prevalence of oral cancer in the region, emphasising the urgent need for public health interventions and improved early detection strategies. Enhancing awareness around risk factors like Toombak, tobacco, and alcohol for tackling this growing health crisis.

Curious about the key insights and their implications for health economics? Look into the full article to find out more!

#SyenzaNews #HealthEconomics #Oncology #GlobalHealth

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.